Ensysce Biosciences (ENSC) Assets (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Assets of $7.5 million for Q4 2025, up 33.15% year-over-year from $5.6 million in Q4 2024, and up 134.39% quarter-over-quarter from $3.2 million in Q3 2025.
Ensysce Biosciences (ENSC) Assets (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Assets for 9 consecutive years, with $7.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets rose 33.15% year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $7.5 million (up 33.15% YoY), while the FY2025 annual figure was $7.5 million, up 33.15% from the prior year.
- Assets improved to $7.5 million in Q4 2025 per ENSC's latest filing, from $3.2 million in the prior quarter.
- Across five years, Assets topped out at $16.4 million in Q4 2021 and bottomed at $1.1 million in Q2 2021.
- Historically, Assets has averaged $6.3 million across 5 years, with a median of $5.6 million in 2024.
- On a YoY basis, Assets climbed as much as 4566.58% in 2021 and fell as far as 92.03% in 2021.
- Ensysce Biosciences' Assets stood at $16.4 million in 2021, then sank by 64.15% to $5.9 million in 2022, then slumped by 53.98% to $2.7 million in 2023, then jumped by 106.69% to $5.6 million in 2024, then surged by 33.15% to $7.5 million in 2025.
- Business Quant data shows ENSC's Assets at $7.5 million in Q4 2025, $3.2 million in Q3 2025, and $5.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 7.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.45 Mn |
| Sep 30, 2025 | 3.18 Mn |
| Jun 30, 2025 | 5.57 Mn |
| Mar 31, 2025 | 4.61 Mn |
| Dec 31, 2024 | 5.60 Mn |
| Sep 30, 2024 | 9.38 Mn |
| Jun 30, 2024 | 2.80 Mn |
| Mar 31, 2024 | 5.07 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 6.36 Mn |
| Mar 31, 2023 | 3.91 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | 8.29 Mn |
| Jun 30, 2022 | 7.95 Mn |
| Mar 31, 2022 | 12.37 Mn |
| Dec 31, 2021 | 16.42 Mn |
| Sep 30, 2021 | 1.07 Mn |
| Jun 30, 2021 | 1.07 Mn |
| Mar 31, 2021 | 12.98 Mn |